Tigocin2% w/w

Tigocin 2% w/w ointment is indicated for the topical treatment of impetigo (skin diseases) due to Staphylococcus aureus and Streptococcus pyogenes. It is also indicated in folliculitis, furunculosis.

Topical Antibiotic preparations

Tigocin 2% w/w is a naturally occurring antibiotic. This antibacterial agent is produced by fermentation using the organism Pseudomonas fluorescens. It is active against a wide range of bacteria (e.g. Staphylococcus aureus including methicillin-resistant strains and Streptococcus pyogenes) those responsible for the majority of skin infections. It is also active against gram-negative pathogens, such as Escherichia coli and Haemophilus influenzae. Tigocin 2% w/w inhibits bacterial protein synthesis by reversibly and specifically binding to bacterial isoleucyl transfer-RNA synthetase.

A small amount of Bactropen ointment should be applied to the affected area 3 times daily for up to 10 days. The safety and effectiveness of Tigocin 2% w/w ointment have been established in the age range of 2 months to 16 years.

A small amount of Bactropen ointment should be applied to the affected area 3 times daily for up to 10 days. The safety and effectiveness of Tigocin 2% w/w ointment have been established in the age range of 2 months to 16 years.

No drug interaction has been identified with Tigocin 2% w/w ointment.

The drug is contraindicated in individuals with a history of hypersensitivity reactions to Tigocin 2% w/w or any of the components of the preparation.

Reported side effects are burning, stinging or pain, itching and some patient may be suffered rash, nausea, erythema, dry skin, tenderness, swelling, contact dermatitis and increased exudate.

Reproduction studies on Tigocin 2% w/w ointment in animals have revealed no evidence of harm to the foetus. As there is no clinical experience on it’s use during pregnancy, Tigocin 2% w/w ointment should only be used in pregnancy when the potential benefits outweigh the possible risks of treatment.It is unknown whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Tigocin 2% w/w ointment is administered to a nursing woman.

Tigocin 2% w/w ointment is not for ophthalmic or intra-nasal use. As with other antibacterial products, prolonged use may result in overgrowth of non-susceptible organisms, including fungi. When Tigocin 2% w/w is used on the face care should be taken to avoid the eyes. This is not suitable in conjunction with cannulae and at the site of central venous cannulation. In the event of a sensitization or severe local irritation from Tigocin 2% w/w ointment, usage should be discontinued and appropriate alternative therapy for the infection instituted. Mixing of Tigocin 2% w/w ointment with other preparations causes risk of dilution, resulting in a reduction of the antibacterial activity and potential loss of stability of the Tigocin 2% w/w in the ointment.

There is currently limited data with overdose of Tigocin 2% w/w ointment. In the event of overdose, the patient should be treated supportively with appropriate monitoring as necessary.

Keep below 25° C temperature, protected from light and moisture. Do not keep in freeze. Keep out of the reach of children.

Topical Antibiotic preparations

Tigocin 2% w/w is a naturally occurring antibiotic. This antibacterial agent is produced by fermentation using the organism Pseudomonas fluorescens. It is active against a wide range of bacteria (e.g. Staphylococcus aureus including methicillin-resistant strains and Streptococcus pyogenes) those responsible for the majority of skin infections. It is also active against gram-negative pathogens, such as Escherichia coli and Haemophilus influenzae. Tigocin 2% w/w inhibits bacterial protein synthesis by reversibly and specifically binding to bacterial isoleucyl transfer-RNA synthetase.

Reproduction studies on Tigocin 2% w/w ointment in animals have revealed no evidence of harm to the foetus. As there is no clinical experience on it’s use during pregnancy, Tigocin 2% w/w ointment should only be used in pregnancy when the potential benefits outweigh the possible risks of treatment.It is unknown whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Tigocin 2% w/w ointment is administered to a nursing woman.